A Study to Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment

Condition:   Multiple Sclerosis, Relapsing-Remitting Intervention:   Drug: Natalizumab Sponsor:   Biogen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials